NeuroBo Pharmaceuticals (NeuroBo Pharmaceuticals) 3-Year EPS without NRI Growth Rate : 80.90% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is NeuroBo Pharmaceuticals 3-Year EPS without NRI Growth Rate?

NeuroBo Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $-1.03.

During the past 3 years, the average EPS without NRI Growth Rate was 80.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 66.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of NeuroBo Pharmaceuticals was 80.90% per year. The lowest was -352.00% per year. And the median was 54.20% per year.

Competitive Comparison of NeuroBo Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, NeuroBo Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroBo Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroBo Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where NeuroBo Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.

NeuroBo Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

NeuroBo Pharmaceuticals (NAS:NRBO) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

NeuroBo Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of NeuroBo Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroBo Pharmaceuticals (NeuroBo Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroBo Pharmaceuticals Inc (NAS:NRBO) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Berkeley Street, Office 19th Floor, Boston, MA, USA, 02116

Website

https://www.neurobopharma.com

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused primarily on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of nonalcoholic steatohepatitis (NASH), obesity, and type 2 diabetes (T2D): DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Executives

James Patrick Tursi	director	106 ASHLEY COURT, MOORESTOWN NJ 08057
Marshall H Woodworth	officer: Acting Chief Financial Officer	C/O NEUROBO PHARMACEUTICALS, INC., 545 CONCORD AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mark A Glickman	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Joseph Hooker	officer: Interim CEO and President	C/O NEUROBO PHARMACEUTICALS, INC., 200 BERKELEY ST, OFFICE 19TH FLOOR, BOSTON MA 02116
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
E&healthcare Investment Fund Ii	10 percent owner	16TH FLOOR, YEOKSAM I-TOWER, 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 06211
E&investment, Inc.	10 percent owner	16TH FLOOR, YEOKSAM I-TOWER, B/D 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 00000
Hyung Heon Kim	director	C/O DONG-A ST & DONG-A SOCIO GROUP, 64 CHEONHO DAERO, DONGDAEMUN-GU, SEOUL M5 00000
Andrew I Koven	director	3 COLUMBUS CIRCLE, SUITE 1710, C/O ARALEZ PHARMACEUTICALS INC., NEW YORK NY 10019
Na Yeon Kim	director, 10 percent owner	C/O NEUROBO PHARMACEUTICALS, INC., 177 HUNTINGTON AVENUE, SUITE 1700, BOSTON MA 02115
Richard Kang	director	9451 SUNNYFIELD COURT, POTOMAC MD 20854
D Gordon Strickland	director	C/O AMPEX CORPORATION, 1228 DOUGLAS AVENUE, REDWOOD CITY CA 94063
Ben Gil Price	officer: CEO and President	8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Akash Bakshi	director, officer: SVP and COO	602 BAINBRIDGE STREET, FOSTER CITY CA 94404